红斑狼疮皮肤表现的管理:一项系统综述
该系统综述检索1990年至2019年3月的文献,纳入107项研究共7343例皮肤型红斑狼疮(CLE)患者,评估11类治疗。结论认为局部钙调神经磷酸酶抑制剂、羟氯喹和沙利度胺有中等证据支持,贝利尤单抗有中等数据支持,但高质量临床试验数据匮乏。
要点
- 局部钙调神经磷酸酶抑制剂有中等证据,尤其作为面部等高风险区域的激素替代药。
- 羟氯喹有中等证据,是SLE患者的一线治疗。
- 沙利度胺有中等证据但毒性风险显著,贝利尤单抗有中等数据支持。
核心结论
- CLE有多种局部、系统和生物制剂治疗选择,疗效与毒性平衡各异,但高质量临床试验数据匮乏。
研究设计与样本
- 系统综述检索Medline、Embase、Scopus和Cochrane CENTRAL从1990年至2019年3月,纳入临床试验、观察性研究或病例系列(≥5例患者),共107项研究、7343例患者。
主要发现
- 107项研究调查了11类治疗,包括局部钙调神经磷酸酶抑制剂13项、防晒5项、R-沙丁胺醇霜2项、抗疟药22项、合成DMARDs 10项、维A酸类2项、沙利度胺/来那度胺22项、生物制剂15项、静脉免疫球蛋白3项、激光6项和其他7项。
关键数值与推荐
- 局部钙调神经磷酸酶抑制剂有中等证据,尤其作为面部等激素并发症高风险区域的激素替代药。
- 羟氯喹有中等证据,是SLE患者的一线治疗。
- 沙利度胺有中等证据但毒性风险显著,贝利尤单抗有中等数据支持。
- 一般措施包括戒烟、防晒和优化维生素D水平。
临床怎么用
- 临床可考虑局部钙调神经磷酸酶抑制剂作为面部等高风险区域的激素替代,SLE患者首选羟氯喹,使用沙利度胺需权衡毒性风险。
局限性
- 高质量临床试验数据匮乏,需要进一步试验以更好理解CLE的最佳管理,特别是特定亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating, causing significant psychological distress, and sometimes scarring. OBJECTIVES: We sought to comprehensively present the evidence for different treatment modalities in patients with cutaneous manifestations of lupus erythematosus (LE). METHODS: Medline, Embase, Scopus and Cochrane CENTRAL were searched electronically from 1990 to March 2019, using keywords related to cutaneous lupus and synonyms and treatment. Articles retrieved were screened for relevance, including reference lists of retrieved reviews. We included clinical trials, observational studies or case series with ≥5 patients focussing on treatment of CLE, with or without SLE. RESULTS: The search identified 6637 studies, of which 107 were included. Each study commonly included a heterogeneous mixture of CLE subtypes, with or without SLE. The 107 included studies investigated 11 different categories of treatment in 7343 patients. Treatments included topical calcineurin inhibitors (13 studies), sun protection (5 studies), R-salbutamol cream (2 studies), antimalarials (22 studies), synthetic DMARDs (10 studies), retinoids (2 studies), thalidomide/lenalidomide (22 studies), biologic therapies (15 studies), intravenous immune globulin (3 studies), laser (6 studies) and other therapies (7 studies). General measures to be considered include smoking cessation, sun protection measures and optimisation of vitamin D levels. Moderate evidence exists for benefit with topical CNIs, particularly as a steroid sparing agent in areas at high risk of steroid complications (e.g. facial skin). There is moderate evidence for hydroxychloroquine, which is first-line in SLE patients, limited evidence to support other synthetic DMARDs, and moderate evidence supporting thalidomide but with significant risk of toxicity. Of biologic therapies, there are moderate data to support belimumab. Limited evidence exists for other therapies. CONCLUSION: Many management options are available for CLE, including topical, systemic and biologic therapies, with a variable balance of efficacy and toxicity. There is a paucity of high-quality clinical trial data. Further trials are required to better understand optimal management of CLE, particularly in specific subgroups.
引用
- Fairley JL, Oon S, Saracino AM, et al. Management of cutaneous manifestations of lupus erythematosus: A systematic review. Semin Arthritis Rheum. 2019. PMID: 31526594. doi:10.1016/j.semarthrit.2019.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。